
Please try another search
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 and influenza combined. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, Adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also focusing on products candidates for respiratory syncytial virus and malaria. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Name | Age | Since | Title |
---|---|---|---|
James F. Young | 68 | 2010 | Independent Chairman of the Board |
Richard Huntington Douglas | 70 | 2010 | Independent Director |
Rachel K. King | 64 | 2018 | Independent Director |
David M. Mott | 58 | 2020 | Independent Director |
John Charles Jacobs | 55 | 2023 | President, CEO & Director |
Margaret G. McGlynn | 64 | 2020 | Independent Director |
Gregg Huber Alton | 57 | 2020 | Independent Director |
Richard J. Rodgers | 56 | 2022 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review